Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: An electrophysiologic study

Clinical Breast Cancer

Volumn 7, Issue 1, 2006, Pages 67-78

  Kreukels, Baudewijntje P C ^a   Schagen, Sanne B ^a   Ridderinkhof, K Richard ^b,c   Boogerd, Willem ^a,d   Hamburger, Hans L ^d   Muller, Martin J ^a   van Dam, Frits S A M ^a,b  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Cognitive deficits; Information processing; Long term side effects; Neurotoxicity; P3

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; TAMOXIFEN; THIOTEPA;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRESS SYNDROME; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESPONSE; ELECTROENCEPHALOGRAPHY; FATIGUE; FEMALE; HIGH RISK POPULATION; HUMAN; INFORMATION PROCESSING; INTERVIEW; LATENT PERIOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROPSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 33744967562     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.n.015     Document Type: Article

References (49)

1. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20:485-493.
2. Brezden CB, Phillips KA, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000; 18:2695-2701.
3. Castellon SA, Ganz PA, Bower JE, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004; 26:955-969.
4. Tchen N, Juffs HG, Downie FP, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003; 21:4175-4183.
5. Wefel JS, Lenzi R, Theriault RL, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004; 100:2292-2299.
6. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 1995; 4:61-66.
7. van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90:210-218.
8. Schagen SB, Hamburger HL, Muller MJ, et al. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol 2001; 51:159-165.
9. Kreukels BP, Schagen SB, Ridderinkhof KR, et al. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 2005; 94:53-61.
10. Goodin DS. Clinical utility of long latency 'cognitive' event-related potentials (P3): the pros. Electroencephalogr Clin Neurophysiol 1990; 76:2-5.
11. Saito H, Yamazaki H, Matsuoka H, et al. Visual event-related potential in mild dementia of the Alzheimer's type. Psychiatry Clin Neurosci 2001; 55:365-371.
12. Van der Molen MW, Bashore TR, Halliday R, et al. Chronopsychophysiology: mental chronometry augmented by psychophysiological time markers. In: Jennings JR, Coles MGH, eds. Handbook of Cognitive Psychophysiology: Central and Autonomic Nervous System Approaches. Chichester: John Wiley & Sons Ltd; 1991:9-178.
13. Barry RJ, Johnstone SJ, Clarke AR. A review of electrophysiology in attention-deficit/hyperactivity disorder. II. Event-related potentials. Clin Neurophysiol 2003; 114:184-198.
14. van der Stelt O, Frye J, Lieberman JA, et al. Impaired P3 generation reflects high-level and progressive neurocognitive dysfunction in schizophrenia. Arch Gen Psychiatry 2004; 61:237-248.
15. Heukrodt C, Powazek M, Brown WS, et al. Electrophysiological signs of neurocognitive deficits in long-term leukemia survivors. J Pediatr Psychol 1988; 13:223-236.
16. Anderson-Hanley C, Sherman ML, Riggs R, et al. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 2003; 9:967-982.
17. Meyers CA. Neurocognitive dysfunction in cancer patients. Oncology (Huntingt) 2000; 14:75-79.
18. Tannock IF, Ahles TA, Ganz PA, et al. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004; 22:2233-2239.
19. Sternberg S. The discovery of processing stages: extensions of Donders' method. Acta Psychol 1969; 30:276-315.
20. Sanders AF. Towards a model of stress and human performance. Acta Psychol (Amst) 1983; 53:61-97.
21. Sanders AF. Issues and trends in the debate on discrete vs. continuous processing of information. Acta Psychol 1990; 74:123-167.
22. Rodenhuis S, Bontenbal M, Beex LV, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003; 349:7-16.
23. Schagen SB, van Dam FS, Muller MJ, et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85:640-650.
24. Derogatis LR, Lipman RS, Rickels K, et al. The Hopkins Symptom Checklist (HSCL). A measure of primary symptom dimensions. Mod Probl Pharmacopsychiatry 1974; 7:79-110.
25. Hesbacher PT, Rickels K, Morris RJ, et al. Psychiatric illness in family practice. J Clin Psychiatry 1980; 41:6-10.
26. Hough RL, Landsverk JA, Jacobsen GF. The use of psychiatric screening scales to detect depression in primary care patients. In: Attkinsson CC, Zich JM, eds. Depression in Primary Care: Screening and Detection. New York: Routledge; 1990.
27. Wald FDM, Mellenbergh GJ. De verkorte versie van de Nederlandse vertaling van de Profile of Mood States (POMS). Ned Tijdschr Psychol 1990; 45:86-90.
28. Regine WF, Schmitt FA, Scott CB, et al. Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. Int J Radiat Oncol Biol Phys 2004; 58:1346-1352.
29. de Jong N, Candel MJ, Schouten HC, et al. Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy. Ann Oncol 2004; 15:896-905.
30. Smets EMA, Garssen B, Bonke B. Het meten van vermoeidheid met de Multidimensionele Vermoeidheids Index (MVI-20): een handleiding. Amsterdam: Medische Psychologie, Academisch Medisch Centrum; 1995.
31. Smulders FT, Kok A, Kenemans JL, et al. The temporal selectivity of additive factor effects on the reaction process revealed in ERP component latencies. Acta Psychol (Amst) 1995; 90:97-109.
32. Hackley SA, Miller J. Response complexity and precue interval effects on the lateralized readiness potential. Psychophysiology 1995; 32:230-241.
33. Kok A. Event-related-potential (ERP) reflections of mental resources: a review and synthesis. Biol Psychol 1997; 45:19-56.
34. Lorist MM, Snel J, Kok A. Influence of caffeine on information processing stages in well rested and fatigued subjects. Psychopharmacology (Berl) 1994; 113:411-421.
35. Nieuwenhuis S, Aston-Jones G, Cohen JD. Decision making, the P3, and the locus coeruleus-norepinephrine system. Psychol Bull 2005; 131:510-532.
36. Johnson R Jr. The amplitude of the P300 component of the event-related potential: review and synthesis. Adv Psychophysiol 1988; 3:69-137.
37. Smulders FT. The selectivity of age effects on information processing [unpublished doctoral dissertation]. Amsterdam: University of Amsterdam; 1993.
38. Keller J, Hicks BD, Miller GA. Psychophysiology in the study of psychopathology. In: Cacioppo JT, Tassinary LG, Berntson GG, eds. Handbook of Psychophysiology. 2nd ed. Cambridge, MA: Cambridge UP; 2000:719-750.
39. Wefel JS, Kayl AE, Meyers CA. Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer 2004; 90:1691-1696.
40. Veltmeyer MD, Clark CR, McFarlane AC, et al. Integrative assessment of brain and cognitive function in post-traumatic stress disorder. J Integr Neurosci 2005; 4:145-159.
41. Andrykowski MA, Cordova MJ, McGrath PC, et al. Stability and change in posttraumatic stress disorder symptoms following breast cancer treatment: a 1-year follow-up. Psychooncology 2000; 9:69-78.
42. Mundy EA, Blanchard EB, Cirenza E, et al. Posttraumatic stress disorder in breast cancer patients following autologous bone marrow transplantation or conventional cancer treatments. Behav Res Ther 2000; 38:1015-1027.
43. Eberling JL, Wu C, Tong-Turnbeaugh R, et al. Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage 2004; 21:364-371.
44. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2000; 64:165-176.
45. Ernst T, Chang L, Cooray D, et al. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst 2002; 94:592-597.
46. Sherwin BB, Tulandi T. "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab 1996; 81:2545-2549.
47. Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 2002; 13:1387-1397.
48. Pierson A, Ragot R, Van Hooff J, et al. Heterogeneity of informstion-processing alterations according to dimensions of depression: an event-related potentials study. Biol Psychiatry 1996; 40:98-115.
49. Farquhar C, Basser R, Marjoribanks J, et al. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database Syst Rev 2003; (1):CD003139.